Sorafenib, a multi-kinase inhibitor that inhibits Raf-1, B-Raf, VEGF receptors, and platelet growth factor receptor, is the first-line systemic therapy that has demonstrated a significant increase in mean overall survival in patients with advanced HCC. This evidence concerns the gene BRAF and hepatocellular carcinoma.